We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+22.97%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.81B
AUM Growth
-$1.23B
Cap. Flow
-$2B
Cap. Flow %
-34.5%
Top 10 Hldgs %
69.35%
Holding
53
New
7
Increased
14
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$374M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$100M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$96.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$81.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$60.1M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.23B
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$257M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$87.6M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$80.8M
5
QURE icon
uniQure
QURE
+$64.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$6.12B
$43.1M 0.74%
2,800,000
– –
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$39.4M 0.68%
3,232,142
+232,142
+8% +$3.24M
OLMA icon
28
Olema Pharmaceuticals
OLMA
$1.05B
$35.6M 0.61%
+876,986
New +$41.1M
AMRN
29
Amarin Corp
AMRN
$304M
$29.3M 0.51%
300,000
– –
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$29.2M 0.5%
4,365,000
+165,000
+4% +$1.03M
RLAY icon
31
Relay Therapeutics
RLAY
$4.21B
$20.8M 0.36%
500,000
– –
BDTX icon
32
Black Diamond Therapeutics
BDTX
$111M
$20.5M 0.35%
640,000
+37,500
+6% +$1.23M
ADAP
33
DELISTED
Adaptimmune Therapeutics
ADAP
$19.1M 0.33%
3,550,000
-7,450,000
-68% -$40.5M
ITOS
34
DELISTED
iTeos Therapeutics
ITOS
$15.6M 0.27%
460,000
– –
PNT
35
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$13.9M 0.24%
1,000,000
– –
RNAM
36
DELISTED
Avidity Biosciences
RNAM
$13.9M 0.24%
545,000
– –
FENC icon
37
Fennec Pharmaceuticals
FENC
$385M
$12.4M 0.21%
1,670,000
– –
GNCA
38
DELISTED
Genocea Biosciences, Inc.
GNCA
$12.3M 0.21%
5,084,184
– –
MNKD icon
39
MannKind Corp
MNKD
$1.28B
$11M 0.19%
+3,500,000
New +$9.18M
SNDX icon
40
Syndax Pharmaceuticals
SNDX
$1.79B
$10M 0.17%
+450,000
New +$9.33M
TNGX icon
41
Tango Therapeutics
TNGX
$4.56B
$9.15M 0.16%
800,000
– –
CUE icon
42
Cue Biopharma
CUE
$113M
$5.66M 0.1%
15,083
-47,250
-76% -$18.9M
ATNX
43
DELISTED
Athenex, Inc. Common Stock
ATNX
$4.12M 0.07%
18,625
-144,625
-89% -$35.6M
NKTR icon
44
CALL
Nektar Therapeutics
NKTR
$2.5B
$26K ﹤0.01%
+6,667
New +$1.72M
ALT icon
45
Altimmune
ALT
$591M
– –
-2,000,000
Closed -$26.4M
KPTI icon
46
Karyopharm Therapeutics
KPTI
$44.4M
– –
-400,000
Closed -$87.6M
KYMR icon
47
Kymera Therapeutics
KYMR
$8.83B
– –
-49,400
Closed -$1.6M
QURE icon
48
uniQure
QURE
$3.21B
– –
-1,750,000
Closed -$64.5M
RAPT
49
DELISTED
RAPT Therapeutics
RAPT
– –
-71,875
Closed -$18.5M
ALIM
50
DELISTED
Alimera Sciences
ALIM
– –
-415,999
Closed -$2.02M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Avoro Capital Advisors held 53 positions worth $5.81B, down 18% from $7.04B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors withdrew a net $2B in Q4 2020, closing 9 positions and reducing 8 holdings. Its most notable exit was Immunomedics Inc, an estimated $2.23B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 67% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in United Therapeutics worth $433M.

  • Avoro Capital Advisors's largest Q4 2020 buy was United Therapeutics: 2,850,000 shares worth $433M.
  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020, an estimated $100M increase.
  • Avoro Capital Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $80.8M.
  • Avoro Capital Advisors fully exited Immunomedics Inc in Q4 2020, selling an estimated $2.23B.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.81B portfolio in Q4 2020.
  • Avoro Capital Advisors opened 7 new positions and closed 9 in Q4 2020.
  • Avoro Capital Advisors's portfolio value fell 18% quarter-over-quarter to $5.81B.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.